Trial Profile
Phase 1/2 study of S-288310 in patients with bladder cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Dec 2016
Price :
$35
*
At a glance
- Drugs S 288310 (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shionogi
- 20 Dec 2016 Primary endpoint of immunological assessment (in vitro cytotoxic T lymphocytes response) has not been met, according to result published in the Annals of Oncology.
- 20 Dec 2016 Results published in the Annals of Oncology
- 01 Oct 2013 Interim results presented at the 2013 European Cancer Congress.